Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Apr 30;17(4):1802-1806.
doi: 10.21037/jtd-24-1867. Epub 2025 Apr 28.

Novel neoadjuvant immunotherapy treatment and surveillance strategies in resectable esophageal cancer: innovation leads to improved outcomes

Kenneth M Williams  1   2 , Kian C Banks  1   2 , Jeffrey B Velotta  1   3   4
Affiliations
Editorial

Novel neoadjuvant immunotherapy treatment and surveillance strategies in resectable esophageal cancer: innovation leads to improved outcomes

Kenneth M Williams et al. J Thorac Dis. .
No abstract available

Keywords: Thoracic surgery; circulating tumor DNA (ctDNA); esophageal cancer; neoadjuvant treatment; phase 1b trial.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-1867/coif). J.B.V. serves as an unpaid editorial board member of Journal of Thoracic Disease from September 2024 to August 2026. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res 2005;11:2947-53. 10.1158/1078-0432.CCR-04-1469 - DOI - PubMed
    1. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20:1506-17. 10.1016/S1470-2045(19)30626-6 - DOI - PubMed
    1. Kelly RJ, Landon BV, Zaidi AH, et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat Med 2024;30:1023-34. 10.1038/s41591-024-02877-z - DOI - PMC - PubMed
    1. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84. 10.1056/NEJMoa1112088 - DOI - PubMed
    1. Morgan E, Soerjomataram I, Rumgay H, et al. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology 2022;163:649-658.e2. 10.1053/j.gastro.2022.05.054 - DOI - PubMed

LinkOut - more resources